A patient with chronic granulocytic leukemia in acute blastic transformation was treated with mithramycin, an RNA synthesis inhibitor, after in vitro exposure of her leukemic cells to mithramycin showed differentiation to normal appearing granulocytes. Mithramycin therapy in vivo resulted in a prompt and dramatic hematologic response. Before therapy, the patient's leukemic cells had high levels of transcription of the cellular myc and abl protooncogenes. After initiation of therapy, protooncogene mRNA decreased rapidly. These observations indicate that mithramycin can induce differentiation both in vitro and in vivo and suggest that such changes may be associated with altered oncogene expression.
Introduction
Chronic granulocytic leukemia (CGL)' is a myeloproliferative disorder associated in >90% of cases with the Philadelphia chromosome (Ph') [t(9;22)(q34;ql 1)] (1, 2) . After a variable period of time, the majority of patients enter a terminal phase that may resemble an acute blastic leukemia (blast crisis). About two-thirds of blast-phase CGLs have recognizable myeloblast or promyelocyte morphology but differ from de novo acute myelogenous leukemia in that they are rarely sensitive to cytotoxic chemotherapy. A differentiation model has been developed using leukemic cell lines that can be induced to differentiate in vitro into cells with the characteristics of normal hematopoietic end cells (3) . Upon differentiation, the leukemic cells cease to proliferate and lose their ability to cause leukemia when transplanted into animals. A murine model also exists wherein the survival time of mice inoculated with syngeneic differentiation-sensitive leukemia cells is significantly improved if they are subsequently treated with a differentiation-inducing agent (4) . A question of profound therapeutic importance is whether the leukemic myeloblasts in CGL can be induced to differentiate into functional granulocytes.
Several lines of evidence indicate that abnormal expression of oncogenes (5) may be important in the pathogenesis of CGL as well as other neoplasms (6, 7) . A protooncogene, cabl, the cellular homologue of the transforming sequence of the Abelson murine leukemia virus (8) , is ordinarily located on chromosome 9q34 (9) and becomes translocated to chromosome 22 with the Ph' translocation (10) . Another protooncogene of interest in CGL is c-myc, the cellular homologue of the transforming sequence of the avian myelocytomatosis virus MC29 (1 1). C-myc is located on chromosome 8 (12) and is involved in translocations involving chromosomes 14 (13) (heavy chain locus), 2, or 22 (light chain loci) in Burkitt's lymphoma cells (14, 15) . The c-myc gene is highly amplified in the human promyelocytic cell line HL60 (16) , as well as in other cell lines (17, 18) , resulting in raised levels of c-myc mRNA. C-myc has also been found to be transcriptionally active in normal hematopoietic tissue as well as in CGL cells (19, 20) . Recent evidence indicates that the product c-myc encodes for is a nuclear protein capable of binding to DNA (21) , and that levels of both c-myc-directed mRNA and c-myc protein are quickly increased after activation of cells with mitogens (22) . While the function of the c-myc gene product is not yet clear, it has been postulated that it is involved in the control of cellular proliferation (21, 22) .
We report here a patient with CGL who had an acute blast transformation associated with enhanced expression of c-abl and c-myc genes, whom we treated with mithramycin, an inhibitor of RNA synthesis (23) . There was a prompt reduction in c-abl and c-myc mRNA transcripts, followed soon 30 min at 370C. After precipitation with trichloroacetic acid, incorporation of the tritiated uridine into radiolabeled RNA was quantitated by filtration on GF/C glass filters (Whatman Inc., Clifton, NJ). Quantitative RNA dot blots. RNA was isolated as previously described (25) . Briefly, mononuclear cells were isolated from peripheral blood as described above. The washed cell suspension was extracted with phenol in the presence of vanadyl ribonucleoside and heparin (26). All operations were carried out at 4VC. RNA was further purified by cesium chloride centrifugation. Total cellular RNA was attached to nitrocellulose and hybridized as described by Thomas (27) .
Cloned cDNA probes. The c-abl probe was supplied by Dr. David Baltimore, Massachusetts Institute of Technology, Cambridge, MA (28) . The c-myc probe was obtained from Dr. Robert Gallo, National Cancer Institute, Bethesda, MD (29 On admission, she had a WBC of 206 X 109/liter with 30% myeloblasts and 34% promyelocytes (Fig. 1) . Her course was complicated by the development of fever, painful splenomegaly, thrombocytopenia, the adult respiratory distress syndrome, renal failure, hepatic insufficiency, and gastrointestinal bleeding. Leukapheresis was initiated to control the white count but was only transiently successful (Fig. 1) .
In vitro differentiation. In vitro incubation of mononuclear cells following a 4-h exposure with mithramycin resulted in a rapid increase in the proportion of mature myeloid cells (Fig.   2 ). The number of viable cells varied <10% from base line. No evidence of differentiation was noted in the control cells incubated without mithramycin.
Clinical response. Before therapy, there was a rapid rise of the WBC despite continuous therapy with hydroxyurea. The WBC was only transiently controlled by leukapheresis (Fig. 1) (Fig. 3) . By day 7 of therapy, the patient became afebrile, was weaned off oxygen, and had a striking clinical and biochemical improvement that continued for 3 wk. She received a total of eight doses of mithramycin.
Inhibition of RNA synthesis. Whole blood RNA synthesis was measured serially (Fig. 4) . There was a 40% inhibition of total cellular RNA synthesis by day 2 and an 80% inhibition of RNA synthesis by day six, 1 (31) . This chronic phase is usually superceded by a rapid fatal acute blastic transformation for which there is no known effective treatment (32) . The blasts appear to be derived from a pleuripotential hematopoietic stem cell capable of self-renewal but incapable of maturation (33) . Commonly, the patients die of infection due to a paucity of functional granulocytes.
A question of profound therapeutic importance is whether the leukemic blasts can be induced to mature under certain external conditions (3, 34) . Work done with murine and human leukemic cell lines in vitro has indicated that some leukemic cells can be induced to differentiate into functional hematopoietic cells by a variety of agents, and in doing so lose their proliferative capability (35) . In a murine model, induction of differentiation in vivo is associated with a significant increase in survival (4 We were particularly interested in expression of c-myc and c-abl protooncogenes, in this case because these oncogenes have been implicated in CGL and because the mechanism of activity of mithramycin is inhibition of DNA-dependent RNA synthesis; that is, mithramycin inhibits gene expression. Correlation of oncogene expression and therapeutic intervention has not yet been reported in humans, although c-myc expression decreases dramatically in HL60 cells induced to differentiate in vitro with vitamin D (36). Thus, we were interested to observe that the levels of expression of both the c-myc and cabl protooncogenes in the leukemic cells of our patient decreased dramatically after initiation of mithramycin therapy. These major changes in oncogene expression were observed before any morphological changes occurred.
The association of markedly decreased c-myc and c-abl oncogene expression with evidence for in vivo differentiation of these cells may have simply reflected the altered proliferative state of these cells after treatment with an effective agent (22) . However, a substantial decrease in c-myc and c-abl expression was noted before decreases in either the absolute leukemic cell number or the relative proportion of leukemic blasts to normal cells. Furthermore, although both total cellular and oncogene expression was inhibited by mithramycin, expression of lyso-
